A notable acquisition unfolded on March 20, as Ricupati, SVP & CAO at Cooper Companies (NASDAQ:COO), reported the acquisition of stock options for 54,724 shares in an SEC filing.
What Happened: Revealed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Ricupati, SVP & CAO at Cooper Companies, strategically acquired stock options for 54,724 shares of COO. These options empower Ricupati to buy the company's stock at a favorable exercise price of $69.74 per share.
Currently, Cooper Companies shares are trading down 0.0%, priced at $101.66 during Thursday's morning. This values Ricupati's 54,724 shares at $1,746,924.
About Cooper Companies
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD ...